About: Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) наукова стаття, опублікована у вересні 2007 (uk) article scientifique publié en 2007 (fr) im September 2007 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q62662265-39459F6D-1B35-4B70-95DA-D0AFAF967B22
publication date	2007-08-21 00:00:00Z (xsd:dateTime)
author name string	wds:Q62662265-25B04C7B-080D-4003-8389-5B81584A92D0 wds:Q62662265-5579B84A-1586-40CA-AA72-85CABFAB9D89 wds:Q62662265-8C119F10-49BE-48B3-B122-A7E2B7F2F7BF wds:Q62662265-91AD086A-2AB4-439A-8DC0-AA357C3B6CA1 wds:Q62662265-ED5E0EF8-D745-4576-AA7D-5E684148AE5C
author name string	Jie Zhang Zhao-Qi Wang Cristina Colarossi Weizheng Xu Wokee Min
rdfs:label	Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis (en)
skos:prefLabel	Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis (en)
name	Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis (en)
author	wds:Q62662265-08C08611-4F0D-489C-9C52-2995138112AF wds:Q62662265-105EA1AA-42D3-4BDA-9709-6DB68C00D225 wds:Q62662265-49DB9E09-FBF6-4BFF-B1CE-CEADFECF7427 wds:Q62662265-4B78472E-D075-4970-8ABF-E466372968FD wds:Q62662265-53EE7DBE-6484-4053-8CE4-74CCBBBD779B wds:Q62662265-5A324CE1-47FA-4DFE-A092-4FBC76B3DF0B wds:Q62662265-86C986DD-066F-4E52-BDE2-A5D93783E4D1 wds:Q62662265-AC2CCB6E-7FA0-487F-8A35-7B1988298783 wds:Q62662265-C3B4D555-8795-460F-95D2-B78A43F0C66B
author	Carlo Leonetti Antonella Stoppacciaro Grazia Graziani Pedro Miguel Lacal Federica Ruffini Lucio Tentori Alessia Muzi Marco Scarsella Annalisa Susanna Dorio
title	wds:Q62662265-00CD6EF4-00E9-454C-80E8-40B13BB4031D
title	Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis (en)
page(s)	wds:Q62662265-28CCEE07-2CC2-4C62-BA34-562D8A3CA60B
page(s)	2124-2133
instance of	wds:Q62662265-B35BDB7E-FE17-4C6F-83E9-1375D40BFF1C
instance of	scholarly article
main subject	wds:Q62662265-D4AAF895-DB01-4FFA-9425-2E806FDBEA22
main subject	angiogenesis
PubMed ID	wds:Q62662265-71F62501-D3F5-4BC4-82E3-116DB939FBD5
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17714938
PubMed ID	17714938
published in	wds:Q62662265-95E7001A-2CA9-42E4-9A15-C577199B3FBB
published in	European Journal of Cancer
issue	wds:Q62662265-C56AC65C-FC3E-47BD-B09A-818BCD480DAA
volume	wds:Q62662265-3D6324AA-ED50-404C-8B62-B1F9C7AFB170
issue	14
volume	43
DOI	wds:Q62662265-929D65A4-5D09-49BB-AF1A-65F2C751FF0C
DOI	http://dx.doi.org/10.1016/J.EJCA.2007.07.010
DOI	10.1016/J.EJCA.2007.07.010
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q62662265
is cites work of	PARP inhibitors in ovarian cancer: current status and future promise An update on PARP inhibitors for the treatment of cancer PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets New treatment option for ovarian cancer: PARP inhibitors The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model Poly(Adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy. Increased poly(ADP-ribosyl)ation in skeletal muscle tissue of pediatric patients with severe burn injury: prevention by propranolol treatment. PARP-1 and PARP-2: New players in tumour development. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond Making the best of PARP inhibitors in ovarian cancer Activation of poly(ADP-ribose) polymerase-1 delays wound healing by regulating keratinocyte migration and production of inflammatory mediators Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment Trial watch - inhibiting PARP enzymes for anticancer therapy Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine Exploring and comparing adverse events between PARP inhibitors Profiling placental and fetal DNA methylation in human neural tube defects LRP1 Regulates Retinal Angiogenesis by Inhibiting PARP-1 Activity and Endothelial Cell Proliferation State-of-the-art strategies for targeting the DNA damage response in cancer Understanding specific functions of PARP-2: new lessons for cancer therapy Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model PARP inhibitor combinations in prostate cancer PARP and PARG inhibitors--new therapeutic targets in cancer treatment Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors Inherited variation in the PARP1 gene and survival from melanoma Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells Low doses of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, stimulate angiogenesis by regulating expression of urokinase type plasminogen activator and matrix metalloprotease 2. Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation Anticancer gold(III) peptidomimetics: from synthesis to in vitro and ex vivo biological evaluation.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software